The FDA has approved an expanded indication of AstraZeneca’s benralizumab (Fasenra) in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare, ...

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody-associated vasculitis that typically presents with asthma, eosinophilia and small-to-medium vessel ...

Granulomatosis with polyangiitis (GPA), known as Wegener’s granulomatosis until 2011, is a rare and potentially serious condition that causes inflammation of the small blood vessels and capillaries.

For patients with eosinophilic granulomatosis with polyangiitis (EGPA), rituximab is not superior to the conventional remission induction strategy, according to a study published online July 29 in the ...

Patients with granulomatosis with polyangiitis (GPA) who scored high on a sinonasal symptom test are nearly three times as likely to relapse, according to a new study. These patients reported higher ...

A UK woman Jayne Hardman lost her nose after rare autoimmune disease granulomatosis with polyangiitis caused severe tissue damage. Now fitted with titanium implants, the 48-year-old uses more than 10 ...

Introduction: Granulomatosis with polyangiitis (GPA) is an autoimmune disease leading to necrotizing lesions in the affected tissues. Computed tomography (CT) of paranasal sinuses reveals multiple ...

Granulomatosis with polyangiitis (GPA) is a rare systemic disease classified as a type of systemic vasculitis, which can lead to life‑threatening complications. 1 Pulmonary carcinoid tumors are also ...

Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Eosinophilic Granulomatosis with Polyangiitis - Market Insight, Epidemiology, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's ...

Granulomatosis with Polyangiitis (GPA) is a type of vasculitis that usually affects the upper airways, lungs and kidneys. Granulomatosis with Polyangiitis (GPA) is a disease that belongs to a group of ...